https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Orchard_Rx_LtdOrchard Rx Ltd - Revizia istoricului2026-04-04T02:15:39ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Orchard_Rx_Ltd&diff=434447&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Orchard Rx Ltd listata cu simbolul US.ORTX ==Descriere companie== Orchard Therapeutics plc (https://www.orchard-tx.com/) is a biopharmaceutical company. The Company is engaged in development, manufacturing and commercialization of gene and cell therapies to provide curative therapies to patients suffering from a range of diseases. It is focused on its autologous ex vivo autologous hematopoietic stem cell (HSC) gene therapy approach in approximately...2024-09-18T18:19:21Z<p>Pagină nouă: Pagina dedicata companiei Orchard Rx Ltd listata cu simbolul US.ORTX ==Descriere companie== Orchard Therapeutics plc (https://www.orchard-tx.com/) is a biopharmaceutical company. The Company is engaged in development, manufacturing and commercialization of gene and cell therapies to provide curative therapies to patients suffering from a range of diseases. It is focused on its autologous ex vivo autologous hematopoietic stem cell (HSC) gene therapy approach in approximately...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Orchard Rx Ltd listata cu simbolul US.ORTX<br />
<br />
==Descriere companie==<br />
Orchard Therapeutics plc (https://www.orchard-tx.com/) is a biopharmaceutical company. The Company is engaged in development, manufacturing and commercialization of gene and cell therapies to provide curative therapies to patients suffering from a range of diseases. It is focused on its autologous ex vivo autologous hematopoietic stem cell (HSC) gene therapy approach in approximately three therapeutic disease areas: neurodegenerative, immunological and blood disorders. Its portfolio includes over two commercial-stage products approved in Europe, seven lentiviral-based product candidates in clinical stage development and several other product candidates in preclinical development. The Company’s lead programs are OTL-200, which was approved in the European Union, United Kingdom, Iceland, Liechtenstein and Norway under the brand name Libmeldy for eligible patients with early onset metachromatic leukodystrophy (MLD), and OTL-103, which is being investigated for the treatment of Wiskott Aldrich syndrome (WAS).<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.ORTX" /><br />
<br />
==Ultimele stiri despre Orchard Rx Ltd (US.ORTX)==<br />
<dynamicpagelist><br />
category=US.ORTX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.ORTX]][[Categorie:Stiri despre companii]]</div>Admin